indazoles has been researched along with Metastase in 157 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (2.55) | 18.7374 |
| 1990's | 7 (4.46) | 18.2507 |
| 2000's | 8 (5.10) | 29.6817 |
| 2010's | 119 (75.80) | 24.3611 |
| 2020's | 19 (12.10) | 2.80 |
| Authors | Studies |
|---|---|
| Adomi, S; Banno, E; De Velasco, MA; Fujimoto, S; Fujita, K; Hashimoto, M; Inoguchi, S; Kikuchi, T; Minami, T; Mori, Y; Nakayama, T; Nishimoto, M; Nose, K; Nozawa, M; Saito, Y; Shimizu, N; Uemura, H; Yoshimura, K | 1 |
| Aglietta, M; Ahmad, Q; Bauer, S; Blay, JY; Cesne, AL; Demetri, GD; Dezzani, L; Gelderblom, H; Han, G; Hohenberger, P; Judson, I; Schöffski, P | 1 |
| Costa, RSD; Couto, DHN; Meirelles, IO | 1 |
| Araujo, DM; Chow, W; Frankel, P; Hartner, L; Milhem, M; Okuno, S; Ruel, C; Staddon, A; Undevia, S | 1 |
| Li, J; Liang, X; Shen, Q; Sun, L; Yang, J; Zhang, J; Zuo, T | 1 |
| Campos-Gomez, S; Chacon, M; Del Castillo, C; Dezzani, L; Jenkins, M; Lema Medina, M; Lerzo, G; Lopera, D; Martin, A; Queiroz Muniz, D; Ratto, B; Salman, P; Signorovitch, J; Yang, H; Zhao, J | 1 |
| Barve, M; Bazhenova, L; Besse, B; Blakely, CM; Bowles, DW; Buchschacher, GL; Chae, YK; Chawla, SP; Cho, BC; Chow-Maneval, E; Conkling, P; Cui, N; Demetri, GD; Doebele, RC; Drilon, A; Eng, S; Fakih, M; Farago, AF; Fox, E; Garrido, P; Garrido-Laguna, I; John, T; Johnson, A; Krauss, JC; Liu, SV; Loong, HH; Nieva, J; Overbeck, TR; Paz-Ares, L; Riehl, T; Seto, T; Shaw, AT; Siena, S; Sigal, D; Simmons, B; Steuer, C; Tosi, D; Wilson, TR | 1 |
| Aravantinos, G; Demiri, S; Fountzilas, G; Koliou, GA; Lampropoulou, DI; Pectasides, D; Pentheroudakis, G; Psyrri, A; Razis, E; Samantas, E; Sgouros, J; Zagouri, F | 1 |
| Bernabeu, D; Blay, JY; Casali, PG; Collini, P; Cruz, J; de Alava, E; Diaz-Martin, J; Dopazo, J; Fernandez-Serra, A; Gonzalez-Aguilera, C; Grignani, G; Gutierrez, A; Hindi, N; Karanian, M; Le Cesne, A; Lopez-Guerrero, JA; Lopez-Pousa, A; Luna, P; Marcilla, D; Martin-Broto, J; Moura, DS; Peña-Chilet, M; Penel, N; Redondo, A; Stacchiotti, S | 1 |
| Bhutani, G; Emamekhoo, H; Kyriakopoulos, CE; Matkowskyj, KA; Zarling, L; Ziemlewicz, T | 1 |
| Ando, M; Goto, T; Hiraga, H; Kawai, A; Kobayashi, E; Kunisada, T; Matsumoto, Y; Naka, N; Nakayama, R; Nishida, Y; Okuma, T; Ozaki, T; Tsuchiya, H; Ueda, T; Urakawa, H | 1 |
| Azzouz, F; Braychenko, E; Elaidi, R; Epaillard, N; Moreira, M; Oudard, S; Simonaggio, A; Sun, CM; Thibault, C; Vano, YA | 1 |
| Hattori, Y; Ito, M; Iwata, H; Maeda, O; Mitsuishi, T; Murakami, F; Nagasaka, T; Ogino, H; Uematsu, T | 1 |
| Agulnik, M; Attia, S; Eulo, V; Haarberg, S; Hirbe, AC; Kershner, T; Luo, J; Milhem, M; Monga, V; Moon, CI; Myles, S; Okuno, S; Parkes, A; Robinson, S; Seetharam, M; Toeniskoetter, J; Van Tine, BA | 1 |
| de Geeter, P; Goebell, PJ; Grünwald, V; Herrmann, E; Hogrefe, C; Marschner, N; Merling, M; Panic, A; Potthoff, K; Staehler, M; Vannier, C | 1 |
| Barzaghi, P; Perego, G; Petrelli, F; Vavassori, I | 1 |
| Chun, FKH; Deuker, M; Karakiewicz, PI | 1 |
| Antonescu, CR; Bandlamudi, C; Chi, P; D'Angelo, SP; Dickson, M; Donoghue, M; Gounder, M; Kelly, C; Keohan, ML; Movva, S; Nacev, B; Qin, LX; Rosenbaum, E; Seier, K; Simeone, N; Slotkin, EK; Tap, WD | 1 |
| Asanuma, K; Hagi, T; Nakamura, T; Sudo, A | 1 |
| Grewal, K; Tabbara, IA | 1 |
| Ahn, MJ; Barlesi, F; Chen, D; Chiu, CH; Cho, BC; Day, BM; De Braud, F; Doebele, RC; Drilon, A; Dziadziuszko, R; Farago, AF; Karapetis, CS; Krebs, MG; Li, YC; Lin, CC; Liu, SV; Patel, MR; Siena, S; Wilson, TR | 1 |
| Abbinanti, S; Agulnik, M; Attia, S; Cehic, R; Charlson, J; Helenowski, I; Hirbe, AC; Milhem, M; Mohindra, N; Monga, V; Okuno, S; Oppelt, P; Robinson, S; Schulte, B; Van Tine, BA | 1 |
| Chen, S; Lensing, MM; Lyu, C; Wagner, KU; Weigel, RJ; Ye, Y | 1 |
| Barnes, K; Bendell, JC; Blachly, R; Blakely, L; Earwood, C; Joseph, M; Kuzur, M; Lane, CM; Mainwaring, M; Reddy, C; Shipley, D | 1 |
| Albiges, L; Bacciarelo, G; Brard, C; Escudier, B; Fizazi, K; Guida, A; Lassau, N; Le Teuff, G; Loriot, Y; Massard, C; Matias, M | 1 |
| Doehn, C; Ehneß, R; Goebell, PJ; Grüllich, C; Grünwald, V; Steiner, T; Welslau, M | 1 |
| Cook, G; Goh, V; Kelly-Morland, C; Mallett, S; Montana, G; Nathan, P; Rudman, S | 1 |
| Akaza, H; Shibasaki, Y; Umeyama, Y | 1 |
| Bortlicek, Z; Buchler, T; Chloupková, R; Dusek, L; Fiala, O; Finek, J; Hornova, J; Kiss, I; Kopeckova, K; Kopecky, J; Lakomy, R; Melichar, B; Poprach, A; Slaby, O; Studentova, H; Svoboda, M; Vyzula, R; Zemanova, M | 1 |
| Calareso, G; de Braud, F; Grassi, P; Mennitto, A; Porcu, L; Prisciandaro, M; Procopio, G; Ratta, R; Verzoni, E | 1 |
| Albiges, L; Derosa, L; Escudier, B; Fizazi, K; Guida, A; Loriot, Y; Massard, C | 1 |
| De Lobel, L; De Maeseneer, D; De Meerleer, G; De Wolf, K; Decaestecker, K; Fonteyne, V; Goetghebeur, E; Lumen, N; Ost, P; Rottey, S; Sundahl, N; Vermaelen, K | 1 |
| Kikuchi, E; Mikami, S; Mizuno, R; Oya, M; Shinojima, T; Takamatsu, K | 1 |
| Choi, H; Gupta, S; Kang, HC; Lu, L; Matrana, MR; Tannir, NM; Wei, W | 1 |
| Chen, J; Feng, Z; Gao, J; Gatza, ML; Haffty, BG; Hu, W; Huang, S; Khella, CA; Liu, J; Tomsky, K; White, E; Wu, H; Xia, D; Xie, H; Yue, X; Zhang, C; Zhao, Y | 1 |
| Kim, HJ; Kim, Y; Lee, J; Lee, SJ; Park, SH | 1 |
| Sleijfer, S; Vos, M | 1 |
| Beuselinck, B; Caruana, L; Couchy, G; de Reyniès, A; Job, S; Joniau, S; Laguerre, B; Lerut, E; Oyen, R; Rioux-Leclercq, N; Van Den Eynde, K; Van Poppel, H; Verbiest, A; Wozniak, A; Zucman-Rossi, J | 1 |
| Aghajanian, C; Alvarez Secord, A; Carney, ME; Coleman, RL; Gray, HJ; Hanjani, P; Hu, W; Kehoe, SM; Landrum, LM; Lankes, HA; Pearl, ML; Richardson, DL; Sill, MW; Sood, AK; Van Le, L; Zhou, XC | 1 |
| 'Aho, T; Armitage, JN; Eisen, T; Fife, K; Klatte, T; Matakidou, A; Riddick, AC; Sachdeva, M; Stewart, GD; Welsh, SJ | 1 |
| Yu-Li Su, H | 1 |
| Kushnir, I; Merimsky, O; Soyfer, V | 1 |
| Li, X; Li, Z; Zhao, W | 1 |
| Hendriks, MP; van Kalleveen, MW; Walraven, M | 1 |
| Chen, H; Jia, J; Li, X; Liu, D; Liu, L; Ma, J; Qiao, Y; Wang, W; Wang, Y; Wu, P; Xi, H; Yang, J; Zeng, Y; Zhang, L; Zhao, Y | 1 |
| Bhatia, S; Blom, A; Nghiem, P; Olencki, T; Parvathaneni, U; Tarabadkar, ES; Thomas, H | 1 |
| Ahmad, Q; Azad, A; Carrasco-Alfonso, MJ; Chang, YH; Chung, J; Davis, ID; Guo, J; Han, J; Jin, J; Lee, JL; Lim, HY; Motzer, R; Nanua, B; Oya, M; Rha, SY; Takahashi, S; Tatsugami, K; Uemura, H; Wu, HC | 1 |
| Aboelhassan, R; Barsoum, M; Basaran, M; Erman, M; Esma, K; Hanene, D; Kamel, B; Karaca, B; Memon, MA; Pilipovic, V; Sevinc, A; Slader, C | 1 |
| Fujita, M; Kuroda, T; Mukai, M; Nakai, Y; Nishimura, K; Oka, T; Shioyama, W; Takada, M; Yasui, T | 1 |
| Berindan-Neagoe, I; Calin, GA; Chen, L; Dan Dumitru, C; Fu, X; Fuentes-Mattei, E; Huang, B; Irimie, A; Ivan, C; Jung, EJ; Lehrer, M; Ling, H; Mafra, ACP; Monroig-Bosque, MDM; Monroig-Bosque, PDC; Nagvekar, R; Nikonowicz, EP; Nouraee, N; Pileczki, V; Redis, RS; Rivera, C; Shah, MY; Zhang, S; Zhang, X | 1 |
| Heo, DS; Keam, B; Kim, DW; Kim, M; Kim, TM; Kim, YJ; Moon, KC; Paeng, JC | 1 |
| Basso, U; Berardi, R; Bersanelli, M; Burattini, L; Buti, S; Conti, A; De Giorgi, U; Iuliani, M; Lolli, C; Maruzzo, M; Mazzucchelli, R; Montironi, R; Mosca, A; Piva, F; Santini, D; Santoni, M; Terrone, C | 1 |
| Gao, H; Guo, X; Li, X; Liu, N; Peng, S; Wang, K; Wu, W; Yu, J; Zhan, G; Zhu, Y | 1 |
| Itonaga, I; Iwasaki, T; Kawano, M; Tanaka, K; Tsumura, H | 1 |
| Kaneko, G; Kondo, H; Makabe, H; Nishimoto, K; Okabe, T; Oyama, M; Shirotake, S; Todo, M; Yasumizu, Y | 1 |
| Abbas, H; Alam, T; Faust, G; Nair, A; Paskins, J; Uccello, M | 1 |
| Donskov, F; Fristrup, N | 1 |
| Abe, T; Ando, Y; Fei, S; Feng, H; Guan, W; Hashizume, M; Iwamoto, C; Kibe, S; Koikawa, K; Miyasaka, Y; Mizumoto, K; Moriyama, T; Nakamura, M; Nakata, K; Ohtsuka, T; Ohuchida, K; Shindo, K; Yan, Z; Zheng, B | 1 |
| Ahmad, Q; Bamias, A; Bono, P; Dezzani, L; Estevez, SV; Hawkins, R; Hirschberg, Y; Jonasch, E; Kalofonos, H; Pisal, CB; Procopio, G; Rodriguez, CS; Sánchez, AR; Schmidinger, M; Srihari, N | 1 |
| Bauernhofer, T; Gerritsmann, H; Kratochvill, F; Kretz, M; Loidl, W; Marszalek, M; Mitterberger, M; Mraz, B; Niedersüß-Beke, D; Pfleger, G; Pichler, R; Schmidinger, M; Stöger, H; Tinchon, C; Tulchiner, G; Vogl, U; Wiesinger, CG | 1 |
| Altavilla, A; Attademo, L; De Giorgi, U; De Lisi, D; Pignata, S; Procopio, G; Santini, D; Verzoni, E | 1 |
| Babur, M; Brown, G; Burrows, N; Cawthorne, C; Dive, C; Forster, D; Gieling, RG; Gregory, J; Hiscock, D; Hodgkinson, C; McMahon, A; Morrow, CJ; Radigois, M; Simpson, K; Smigova, A; Williams, KJ; Wilson, I | 1 |
| Bhargava, S; Chen, J; Haas-Kogan, DA; Kolkowitz, I; Matthay, KK; Molinaro, AM; Mueller, S; Olow, A; Orbach, S; Wehmeijer, N; Yang, X | 1 |
| Berney, D; Bex, A; Blank, C; Boleti, E; Chowdhury, S; Haanen, J; Jones, R; Kayani, I; Lim, L; Peters, J; Powles, T; Reynolds, AR; Sahdev, A; Shamash, J; Sharpe, K; Stewart, GD | 1 |
| Brabant, G; Burrows, N; Telfer, B; Williams, KJ | 1 |
| Soulières, D | 1 |
| Ahn, HK; Choi, JY; Choi, SH; Kang, WK; Kim, H; Kim, KM; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS | 1 |
| Bi, C; Credille, KM; Donoho, GP; Manro, JR; Peek, VL; Walgren, RA; Wijsman, JA; Wu, W; Yan, L; Yan, SB | 1 |
| Ammendola, M; Citraro, R; De Sarro, G; Donato Di Paola, E; Gadaleta, CD; Gallelli, L; Mammì, M; Marech, I; Ranieri, G; Russo, E | 1 |
| Carlson, DM; Chiu, YL; Pradhan, RS; Ricker, JL | 1 |
| Barone, C; Bendell, JC; Bloom, J; Kim, JG; Kim, S; Pastorelli, D; Pericay, C; Ricart, AD; Rosbrook, B; Sobrero, AF; Swieboda-Sadlej, A; Tarazi, J; Tournigand, C; Wainberg, ZA | 1 |
| Bauer, S; Hodge, RA; Kasper, B; Kerst, JM; Litière, S; Marreaud, S; Sleijfer, S; van der Graaf, WTA; Verweij, J | 1 |
| Banville, M; Collins, C; Cruz-Muñoz, W; Di Desidero, T; Hashimoto, K; Jaramillo, ML; Kerbel, RS; Man, S; O'Connor-McCourt, MD; Xu, P | 1 |
| Schmidinger, M | 1 |
| Blomqvist, LK; Farnebo, J; Grybäck, P; Harmenberg, U; Laurell, A; Sandström, P; Ullén, A; Wersäll, P | 1 |
| Acharyya, S; Chopra, A; Fay, AP; Haaland, B; Lopes, Gde L | 1 |
| Akaza, H; Eto, M; Fujii, Y; Kamei, Y; Kanayama, H; Naito, S; Ozono, S; Shinohara, N; Tomita, Y; Uemura, H; Umeyama, Y | 1 |
| Ito, T; Kutikov, A | 1 |
| Deng, LL; Lin, P; Liu, Y; Lu, C; Qin, Z; Sun, L | 1 |
| Bjarnason, GA; Bocci, G; Di Desidero, T; Jedeszko, C; Kerbel, RS; Lee, CR; Man, S; Paez-Ribes, M; Xu, P | 1 |
| Cho, YJ; Kim, HS; Kim, SH; Kim, SJ; La Choi, Y; Lee, J; Lee, SJ; Park, SH; Rha, SY; Shin, KH; Yoo, KH | 1 |
| Albiges, L; Carton, E; Escudier, B; Gizzi, M | 1 |
| Bar-Sela, G; Keidar, Z; Naroditsky, I; Semenisty, V | 1 |
| Bex, A; Blank, CU; Broeks, A; de Gruijl, TD; Gadiot, J; Guislain, A; Haanen, JB; Jordanova, ES; Kaiser, A; Sanders, J; van Boven, H | 1 |
| Fukuhara, H; Kato, T; Kawazoe, H; Nishida, H; Sakurai, T; Shibasaki, T; Tomita, Y; Yamagishi, A | 1 |
| Askerova, Z; DeAnnuntis, LL; Escudier, B; Hariharan, S; Motzer, RJ; Rini, BI; Roberts, WG; Rosbrook, B; Tarazi, J | 1 |
| Giri, S; Hahn, AW; Martin, MG; Patel, D; Sluder, H; Vanderwalde, A | 1 |
| Abdollahi, A; Alves, F; Chiblak, S; Fuchs, B; Jannasch, K; Kleeff, J; Lindner, T; Matzke-Ogi, A; Mier, W; Morton, J; Orian-Rousseau, V; Ponta, H; Sansom, O; Schwager, C; Shatirishvili, M; Tawk, B; Warth, A | 1 |
| Ha, SY; Heo, JS; Kim, HC; Kim, KM; Kim, ST; Lauwers, G; Lee, J; Park, C; Park, YS | 1 |
| Ahn, H; Ahn, JH; Hong, B; Hong, JH; Jeong, IG; Koo, DH; Lee, DH; Lee, JL; Park, I; Song, C; You, D | 1 |
| Koo, V; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ | 1 |
| Diaz, J; Pandha, H; Sapunar, F; Sehgal, M; Takyar, S | 1 |
| Bodnar, L; Chrom, P; Semeniuk-Wojtas, A; Spencer, NJ; Stec, R; Szczylik, C | 1 |
| Fan, A; Haas, D; Harshman, L; Lam, A; Li, S; Narayanan, S; Pachynski, R; Poushnejad, S; Srinivas, S; Vaishampayan, U | 1 |
| Eaddy, M; Hackshaw, MD; Holmes, M; Lankford, M; Ogbonnaya, A; Thomas, M | 1 |
| Andrews, GI; Bair, AH; Fishman, MN; Grünwald, V; Jonasch, E; Melichar, B; Oya, M; Rini, BI; Rosbrook, B; Tomita, Y; Ueda, T; Uemura, H | 1 |
| Grünwald, V; Kalanovic, D; Lin, X; Simantov, R | 1 |
| Kim, JH; Lee, JL; Park, I | 1 |
| Bruno, R; Chanu, P; Chen, Y; Claret, L; Mercier, F; Milligan, PA; Rosbrook, B; Yazdi, P; Zheng, J | 1 |
| Fujisawa, M; Harada, KI; Miyake, H; Ozono, S | 1 |
| Chung, J; Joo, J; Joung, JY; Kim, S; Kim, SH; Lee, KH; Seo, HK | 1 |
| Azraq, Y; Eleyan, F; Gill, S; Katz, D; Merimsky, O; Peretz, T | 1 |
| Golčić, M; Petković, M | 1 |
| Alexandre, J; Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Goldwasser, F; Huillard, O; Jouinot, A; Thomas-Schoemann, A; Tlemsani, C; Vidal, M | 1 |
| Alamri, S; Atkinson, B; Baiomy, A; Campbell, M; Corn, P; Elsayes, KM; Jonasch, E; Kalra, S; Matrana, MR; Shetty, A; Tannir, NM; Teegavarapu, P; Xiao, L | 1 |
| Abell, F; Apt, D; Chan, S; Fehrenbacher, L; Gendreau, S; Huizing, M; Laing, R; Petrakova, K; Rooney, I; Roylance, R; Singel, S; Vuylsteke, P; Zhou, J | 1 |
| Allman, K; Beach, J; Elson, P; Garcia, JA; Gilligan, T; Martin, A; Ornstein, MC; Rini, BI; Wood, L | 1 |
| Fishkin, P; Karczmar, GS; Karrison, T; Medved, M; O'Donnell, PH; Oto, A; Stadler, WM; Sweis, RF; Szmulewitz, RZ; Towey, S | 1 |
| Chi, Y; Cui, CX; Du, CX; Song, Y; Sun, Y; Sun, YK; Wang, JW; Yang, L; Zhang, W; Zhou, AP | 1 |
| Aurilio, G; Cossu Rocca, M; Cullurà, D; de Cobelli, O; Iacovelli, R; Nolè, F; Verri, E | 1 |
| de Waal, YR; Leenders, W; Ottevanger, PB; Tops, B; van der Steen, MJ; Westermann, A | 1 |
| Bedke, J; Stühler, V | 1 |
| Abdulfatah, E; Kukreja, G; Nagasaka, M; Sukari, A; Vaishampayan, U | 1 |
| Joshi, A; Kannan, RA; Kothari, R; Menon, S; Noronha, V; Patil, VM; Popat, P; Prabhash, K; Ramaswamy, A; Sable, N; Sahu, A | 1 |
| Bhalla, IP; Bukowski, RM; Choueiri, TK; Elson, P; Ganapathi, R; Golshayan, AR; Jaeger, E; Rini, BI; Sein, N; Sercia, L; Simko, J; Small, EJ; Vaziri, SA; Waldman, FM; Weinberg, V; Wood, L; Zhou, M | 1 |
| Bastien, L; Culine, S; de la Taille, A; Ledbai, S; Patard, JJ; Paule, B | 1 |
| Charlton, A; Chong, ML; Dar, M; Davids, M; Davids, MS; Goh, BC; Hodge, J; Laubscher, K; Ng, SS; Soong, R | 1 |
| Antonarakis, ES; Emadi, A | 1 |
| Hudder, A; Novak, RF; Zheng, J; Zukowski, K | 1 |
| Keating, GM; Sanford, M | 1 |
| Agulnik, M; Chia, S; Clemons, M; Dent, S; Grenci, P; Ivy, P; Leighl, NB; Oza, AM; Pritchard, KI; Taylor, SK; Wang, L | 1 |
| Karakiewicz, PI; Maurin, C; Perrotte, P; Sun, M; Thuret, R | 1 |
| Chae, HJ; Kim, HR; Lee, GH | 1 |
| Chan, AL; Leung, HW | 1 |
| Chowbay, B; Gao, F; Goh, BC; Ivy, P; Koh, TS; Leong, SS; Lim, WT; Ng, QS; Singh, O; Tan, DS; Tan, EH; Thng, CH; Toh, CK | 1 |
| Atkinson, B; Choueiri, TK; Chowdhury, S; Matrana, MR; Tannir, NM; Tsang, C | 1 |
| Brown, CK; Fruehauf, J; Kim, S; Liau, KF; Lutzky, J; McDermott, D; Meric, JB; Niethammer, AG; Rixe, O; Rosbrook, B; Shalinsky, DR | 1 |
| Ahn, H; Ahn, JH; Ahn, S; Ahn, Y; Hong, JH; Kim, CS; Kim, TW; Lee, JL; Park, I; Park, K; Park, S; Song, C | 1 |
| Buonerba, C; De Placido, S; Di Lorenzo, G | 1 |
| Nystrom, KK; Pick, AM | 1 |
| Biondi, G; De Martino, D; Di Dato, V; Garrone, B; Guglielmotti, A; Liguori, L; Mangano, G; Marino, N; Navas, L; Spano, D; Vastolo, V; Zollo, M | 1 |
| Cheng, HC; Cheng, Y; Li, W; Liu, Y; Ma, J; Qiu, L | 1 |
| Daimon, M; Kaino, W; Kameda, W; Karasawa, S; Kato, T; Oizumi, T; Susa, S; Takase, K; Tomita, Y; Wada, K | 1 |
| Carmichael, C; Josephson, DY; Lau, C; Pal, SK | 1 |
| Boleti, E; Chowdury, S; Crabb, SJ; Jones, R; Nathan, P; Powles, T; Protheroe, A; Rashid, S; Sarwar, N; Shamash, J; Stockdale, A; Wilson, P | 1 |
| Amarantidis, K; Chamalidou, E; Chelis, L; Christakidis, E; Dimopoulos, P; Kakolyris, S; Michailidis, P; Prassopoulos, P; Souftas, V; Xenidis, N | 1 |
| Chmielowski, B; Federman, N; Tap, WD | 1 |
| Borker, R; Fonseca, E; Hess, G | 1 |
| Bible, KC; Bossou, AR; Copland, JA; Fisher, KE; Isham, CR; Kumar, R; Lingle, WL; Marlow, L; Negron, V; Sherman, EJ; Smallridge, RC; Suman, VJ | 1 |
| Barrios, CH; Chen, M; Davis, ID; Gladkov, OA; Hawkins, RE; Lee, E; Mardiak, J; McCann, L; Rubin, SD; Salman, P; Sternberg, CN; Szczylik, C; Wagstaff, J; Zarba, JJ | 1 |
| Konovalova, NP | 1 |
| Rini, BI | 1 |
| Mancuso, A; Sternberg, CN | 1 |
| Chun, YS; Jeong, JM; Jung, YJ; Kim, JH; Kim, KE; Park, JW; Shin, DH | 1 |
| Chen, CJ; Chung, JG; Hsu, MH; Huang, LJ; Kuo, SC; Lee, FY; Teng, CM; Yamori, T | 1 |
| Carpano, S; Conti, F; Di Lauro, L; Giannarelli, D; Gionfra, T; Lopez, M; Paoletti, G; Pignatti, F; Vici, P | 1 |
| Bucci, L; Caponigro, F; Di Martino, N; Facchini, G; Fei, L; Iaffaioli, RV; Mantovani, G; Santangelo, M; Tortoriello, A | 1 |
| Borsellino, N; Colucci, G; Gebbia, N; Gebbia, V; Giotta, F; Latteri, MA; Milia, V; Testa, A; Valdesi, M | 1 |
| Amadori, D; Cariello, S; De Matteis, A; Ferrari, M; Frassineti, GL; Lombardi, A; Mustacchi, G; Nanni, O; Nascimben, O; Santoro, A; Scarpi, E; Zoli, W | 1 |
| Aitken, SE; Futter, NG; Irvine, AH; Moors, DE; Stewart, DJ | 1 |
| Button, D; de Graeff, A; Glaholm, J; Leach, MO; Mansi, JL; Newell, DR; Payne, G; Smith, IE | 1 |
| Benson, AB; Neuberg, DS; Pandya, KJ; Robins, HI; Tormey, DC | 1 |
| Basurto, C; Bertusi, M; Bisagni, G; Buzzi, F; Di Costanzo, F; Donati, D; Gori, S; Passalacqua, R | 1 |
| Amoroso, D; Bertelli, G; Ciottoli, GB; Conte, PF; Cusimano, MP; Gulisano, M; Lionetto, R; Pronzato, P; Rosso, R | 1 |
| Gilchrist, K; Grem, JL; Robins, HI; Trump, DL; Wilson, KS | 1 |
| Band, PR; Coppin, CM; Eisenhauer, EA; Maroun, J; Pritchard, K; Stewart, D; Wilson, K | 1 |
27 review(s) available for indazoles and Metastase
| Article | Year |
|---|---|
Second-line tyrosine kinase inhibitor-therapy after immunotherapy-failure.
Topics: Anilides; Axitinib; Carcinoma, Renal Cell; Drug Therapy, Combination; Humans; Immunotherapy; Indazoles; Kidney Neoplasms; Neoplasm Metastasis; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases | 2020 |
PARP Inhibitors in Prostate Cancer.
Topics: Animals; BRCA1 Protein; BRCA2 Protein; Genetic Predisposition to Disease; Humans; Indazoles; Indoles; Male; Mutation; Neoplasm Metastasis; Phenotype; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; PTEN Phosphohydrolase; Treatment Outcome | 2021 |
Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Clinical Trials as Topic; Combined Modality Therapy; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Retreatment; Treatment Outcome | 2017 |
EJC's biennial report on metastatic soft tissue sarcoma: State of the art and future perspectives.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Drug Therapy; Forecasting; Humans; Indazoles; Neoplasm Metastasis; Pyrimidines; Sarcoma; Sulfonamides; Tetrahydroisoquinolines; Trabectedin | 2018 |
Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Doxorubicin; Female; Humans; Indazoles; Male; Neoplasm Metastasis; Neoplasm Staging; Odds Ratio; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Sulfonamides; Treatment Outcome | 2019 |
Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: a position paper of the MeetURO Group.
Topics: Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2019 |
Side-effects associated with targeted therapies in renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Everolimus; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sulfonamides; Sunitinib | 2013 |
Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: a new treatment for metastatic soft tissue sarcoma.
Topics: Angiogenesis Inhibitors; Animals; Humans; Indazoles; Molecular Targeted Therapy; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrimidines; Sarcoma; Signal Transduction; Sulfonamides; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Improving outcomes in metastatic clear cell renal cell carcinoma by sequencing therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Patient Selection; Sirolimus; Treatment Outcome | 2014 |
Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Interferons; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Sunitinib; Survival Analysis | 2014 |
Kidney cancer in 2014: Key advances promise progress for kidney cancer patients.
Topics: Angiogenesis Inhibitors; Carcinogenesis; Carcinoma, Renal Cell; Disease Progression; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Nephrectomy; Nephrons; Organ Sparing Treatments; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2015 |
Axitinib in metastatic renal cell carcinoma.
Topics: Algorithms; Axitinib; Carcinoma, Renal Cell; Disease Progression; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor | 2015 |
Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma-a suitable treatment option: case report and review of anti-angiogenic treatment options.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Female; Hemangioendothelioma, Epithelioid; Humans; Immunohistochemistry; Indazoles; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome | 2016 |
First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2016 |
Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.
Topics: Aged; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Interactions; Drug Monitoring; Humans; Indazoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrimidines; Sarcoma; Sulfonamides | 2016 |
Targeted therapies in metastatic renal cancer in 2009.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factors | 2009 |
Ruthenium-based chemotherapeutics: are they ready for prime time?
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Dimethyl Sulfoxide; Drug Screening Assays, Antitumor; Drugs, Investigational; Humans; Indazoles; Neoplasm Metastasis; Organometallic Compounds; Ruthenium Compounds | 2010 |
Pazopanib: in advanced renal cell carcinoma.
Topics: Anticarcinogenic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Humans; Indazoles; Kidney Neoplasms; Neoplasm Metastasis; Protein-Tyrosine Kinases; Pyrimidines; Sulfonamides | 2010 |
[Treatment of metastatic renal cell carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Immunotherapy; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2011 |
Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib | 2011 |
Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2011 |
Pazopanib for the treatment of metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Interactions; Humans; Indazoles; Kidney Neoplasms; Neoplasm Metastasis; Protein-Tyrosine Kinases; Pyrimidines; Sulfonamides; Treatment Outcome | 2012 |
Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Neoplasm Metastasis; Neoplasms; Protein Kinase Inhibitors | 2012 |
Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease-Free Survival; Drug Substitution; Drugs, Investigational; Endpoint Determination; Humans; Indazoles; Molecular Targeted Therapy; Neoplasm Metastasis; Outcome and Process Assessment, Health Care; Prognosis; Pyrimidines; Sarcoma; Sirolimus; Sulfonamides; Survival Rate; TOR Serine-Threonine Kinases; Treatment Outcome | 2012 |
VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; ErbB Receptors; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein | 2006 |
New treatment approaches in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Erlotinib Hydrochloride; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2006 |
40 trial(s) available for indazoles and Metastase
| Article | Year |
|---|---|
Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Chondrosarcoma; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Progression-Free Survival; Prospective Studies; Pyrimidines; Sulfonamides | 2020 |
First Line Gemcitabine/Pazopanib in Locally Advanced and/or Metastatic Biliary Tract Carcinoma. A Hellenic Cooperative Oncology Group Phase II Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Sulfonamides; Treatment Outcome | 2020 |
Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial.
Topics: Aged; Female; Follow-Up Studies; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Solitary Fibrous Tumors; Sulfonamides; Survival Rate | 2020 |
Phase II trial of pazopanib in patients with metastatic or unresectable chemoresistant sarcomas: A Japanese Musculoskeletal Oncology Group study.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pyrimidines; Sarcoma; Sulfonamides; Treatment Outcome; Young Adult | 2020 |
BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Humans; Indazoles; Ipilimumab; Kidney Neoplasms; Neoplasm Metastasis; Nivolumab; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Sunitinib | 2020 |
A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy.
Topics: Aged; Female; Humans; Indazoles; Male; Neoplasm Metastasis; Progression-Free Survival; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides | 2020 |
First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Diarrhea; Fatigue; Female; Humans; Hypothyroidism; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Pyrimidines; Sulfonamides; Treatment Outcome | 2021 |
Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Osteosarcoma; Prospective Studies; Pyrimidines; Sarcoma; Sulfonamides; Topotecan; Treatment Outcome; Young Adult | 2021 |
A Phase-2 Trial of Single Agent Axitinib as Maintenance Therapy Following First-Line Treatment With Modified FOLFOX/Bevacizumab in Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Treatment Outcome | 2017 |
Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated
Topics: Adult; Aged; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Cell Proliferation; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Imidazoles; Indazoles; Indoles; London; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neoplasms, Second Primary; Positron-Emission Tomography; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome | 2017 |
Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Chemoradiotherapy; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Pyrimidines; Radiosurgery; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Sulfonamides | 2017 |
Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Double-Blind Method; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Placebos; Progression-Free Survival; Proto-Oncogene Mas; Pyrimidines; Sulfonamides; Treatment Outcome | 2018 |
Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Renal Cell; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Sulfonamides; Sunitinib; White People; Young Adult | 2018 |
A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma.
Topics: Adult; Angiogenesis Inhibitors; Female; Humans; Indazoles; Male; Neoplasm Metastasis; Pyrimidines; Sarcoma, Alveolar Soft Part; Sulfonamides | 2019 |
Usefulness of Implementing Comprehensive Pharmaceutical Care for Metastatic Renal Cell Carcinoma Outpatients Treated with Pazopanib.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Incidence; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Medication Adherence; Middle Aged; Neoplasm Metastasis; Outpatients; Patient Compliance; Pyrimidines; Self Report; Sulfonamides; Treatment Outcome | 2019 |
A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Nephrectomy; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Radiopharmaceuticals; Sulfonamides; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Withholding Treatment | 2013 |
Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Disease-Free Survival; Female; Humans; Indazoles; Intestinal Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrimidines; Stomach Neoplasms; Sulfonamides; Survival Rate; Treatment Outcome; Young Adult | 2013 |
Exposure-response (safety) analysis to identify linifanib dose for a Phase III study in patients with hepatocellular carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Pharmaceutical Solutions; Phenylurea Compounds; Tablets; Young Adult | 2013 |
Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Young Adult | 2013 |
Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.
Topics: Adult; Aged; Angiogenesis Inhibitors; Disease-Free Survival; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Placebos; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sarcoma; Sulfonamides; Treatment Outcome | 2014 |
Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma.
Topics: Adult; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Imidazoles; Indazoles; Japan; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma.
Topics: Axitinib; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Protein Kinase Inhibitors; Retrospective Studies | 2015 |
Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Administration Schedule; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pyrimidines; Sulfonamides; Survival Analysis; Treatment Outcome; Urologic Neoplasms | 2016 |
Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Double Bind Interaction; Drug Administration Schedule; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome | 2016 |
Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-c
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; Female; Humans; Indazoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Sulfonamides | 2016 |
Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Contrast Media; Disease Progression; Female; Humans; Indazoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Sulfonamides; Treatment Outcome | 2017 |
Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma-Results From a Tertiary Cancer Center in India.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indazoles; India; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Prospective Studies; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Tertiary Care Centers; Treatment Outcome; Young Adult | 2017 |
A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Breast Neoplasms; Disease Progression; ErbB Receptors; Female; Humans; Indazoles; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platelet-Derived Growth Factor; Pyrimidines; Sulfonamides | 2010 |
Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib | 2011 |
A Phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Anorexia; Asian People; Carcinoma; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Pyrimidines; Sulfonamides; Treatment Outcome; Vomiting | 2011 |
Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Proto-Oncogene Proteins c-kit; Receptors, Vascular Endothelial Growth Factor | 2011 |
An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2012 |
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Cross-Over Studies; Diarrhea; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypertension; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Treatment Outcome | 2013 |
Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Epirubicin; Female; Follow-Up Studies; Humans; Indazoles; Middle Aged; Neoplasm Metastasis; Survival Rate | 1995 |
Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Epirubicin; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Indazoles; Interferon alpha-2; Interferon-alpha; Menopause; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Postmenopause; Premenopause; Recombinant Proteins | 1995 |
Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: a phase II study of the Southern Italy Oncology Group (GOIM).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Administration Schedule; Epirubicin; Female; Humans; Indazoles; Middle Aged; Neoplasm Metastasis | 1997 |
Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: results from a multicenter prospective randomized trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Protocols; Doxorubicin; Drug Interactions; Female; Humans; Indazoles; Middle Aged; Neoplasm Metastasis | 1998 |
Phase II study of lonidamine in metastatic prostatic carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Drug Evaluation; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms | 1991 |
Phase II study of lonidamine in patients with metastatic breast cancer. An Eastern Cooperative Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Drugs, Investigational; Female; Humans; Indazoles; Middle Aged; Neoplasm Metastasis | 1990 |
Lonidamine in advanced colorectal cancer: a phase II study of the Italian Oncology Group for Clinical Research (GOIRC).
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Clinical Trials as Topic; Colorectal Neoplasms; Drug Evaluation; Female; Humans; Indazoles; Italy; Male; Middle Aged; Neoplasm Metastasis; Pyrazoles | 1989 |
91 other study(ies) available for indazoles and Metastase
| Article | Year |
|---|---|
Disseminated intravascular coagulation induced by pazopanib following combination therapy of nivolumab plus ipilimumab in a patient with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disseminated Intravascular Coagulation; Humans; Immune Checkpoint Inhibitors; Indazoles; Ipilimumab; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nivolumab; Pyrimidines; Sulfonamides | 2022 |
Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pyrimidines; Randomized Controlled Trials as Topic; Retrospective Studies; Sarcoma; Sulfonamides; Survival Analysis; Treatment Outcome | 2019 |
[Cost-effectiveness between pazopanib and sunitinib for metastatic renal cancer from the perspective of the Brazilian Unified National Health System].
Topics: Adult; Aged; Antineoplastic Agents; Cost-Benefit Analysis; Female; Humans; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; National Health Programs; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Sunitinib; Treatment Outcome | 2019 |
Coadministration of chemotherapy and PI3K/Akt pathway treatment with multistage acidity/CathB enzyme-responsive nanocarriers for inhibiting the metastasis of breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Carriers; Female; Humans; Indazoles; Maleic Anhydrides; Mice; Nanoparticles; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Polyethyleneimine; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Proto-Oncogene Proteins c-akt; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays | 2019 |
Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America.
Topics: Aged; Carcinoma, Renal Cell; Disease Progression; Everolimus; Female; Humans; Indazoles; Kidney Neoplasms; Latin America; Male; Middle Aged; Neoplasm Metastasis; Practice Patterns, Physicians'; Progression-Free Survival; Pyrimidines; Retrospective Studies; Sulfonamides; Time-to-Treatment | 2019 |
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Topics: Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Gene Fusion; Humans; Indazoles; Male; Membrane Glycoproteins; Middle Aged; Neoplasm Metastasis; Neoplasms; Protein Kinase Inhibitors; Receptor, trkA; Receptor, trkB; Receptor, trkC; Receptors, Nerve Growth Factor; Time Factors; Treatment Outcome | 2020 |
Polycystic Liver Disease in a Patient With Metastatic Renal Cell Carcinoma: A Case Report.
Topics: Aged; Anilides; Carcinoma, Renal Cell; Cysts; Humans; Indazoles; Kidney Neoplasms; Liver Diseases; Male; Neoplasm Metastasis; Pyridines; Pyrimidines; Sulfonamides | 2020 |
Long-term multidisciplinary treatment including proton therapy for a recurrent low-grade endometrial stromal sarcoma and pathologically prominent epithelial differentiation: an autopsy case report.
Topics: Adult; Autopsy; Drainage; Endometrial Neoplasms; Fatal Outcome; Female; Humans; Indazoles; Liver Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Proton Therapy; Pyrimidines; Sarcoma, Endometrial Stromal; Sepsis; Sulfonamides; Young Adult | 2020 |
Treating metastatic clear-cell renal cell carcinoma: beyond immunotherapy.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Immunotherapy; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Nivolumab; Patient Selection; Phenylurea Compounds; Pyridines; Pyrimidines; Quinolines; Sulfonamides; Sunitinib | 2020 |
HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical Outcome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Child; Disease-Free Survival; Female; Genotype; HLA-A Antigens; Humans; Indazoles; Loss of Heterozygosity; Male; Membrane Proteins; Middle Aged; Neoplasm Metastasis; Prognosis; Pyrimidines; Sarcoma, Synovial; Sulfonamides; T-Lymphocytes; Treatment Outcome; Young Adult | 2020 |
Clinical Outcome of Systemic Treatment for Advanced Soft Tissue Sarcoma: Real-Life Perspective in Japan.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Female; Furans; Humans; Indazoles; Japan; Kaplan-Meier Estimate; Ketones; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Pyrimidines; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Survival Analysis; Trabectedin; Treatment Outcome | 2020 |
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins; Young Adult | 2021 |
Targeting Gi/o protein-coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy.
Topics: Animals; Antineoplastic Agents, Immunological; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Epithelium; ErbB Receptors; Female; Humans; Indazoles; Lapatinib; Mammary Glands, Animal; Mice, Transgenic; Neoplasm Metastasis; Pertussis Toxin; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, G-Protein-Coupled; Signal Transduction; Sulfonamides; Trastuzumab; Up-Regulation | 2021 |
Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre.
Topics: Age Factors; Age of Onset; Antineoplastic Agents; Axitinib; Cancer Care Facilities; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Protein Kinase Inhibitors; Treatment Outcome | 2017 |
The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Everolimus; Female; Humans; Indazoles; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Nivolumab; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Sulfonamides; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor Receptor-1 | 2017 |
Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Registries; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2017 |
Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Pyrimidines; Retrospective Studies; Sulfonamides; Treatment Outcome | 2017 |
Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy.
Topics: Adult; Aged; Axitinib; Carcinoma, Renal Cell; Everolimus; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2017 |
Baseline risk stratification or duration of prior therapy predicts prognosis in patients with metastatic renal cell carcinoma treated with axitinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Japan; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Risk Assessment; Treatment Outcome; Young Adult | 2017 |
Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Contrast Media; Disease Progression; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Risk Factors; Salvage Therapy; Sulfonamides; Tomography, X-Ray Computed | 2017 |
Parkin targets HIF-1α for ubiquitination and degradation to inhibit breast tumor progression.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Down-Regulation; Female; Heterografts; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Lung Neoplasms; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mutation; Neoplasm Metastasis; Transfection; Ubiquitin-Protein Ligases; Ubiquitination | 2017 |
Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Female; Humans; Indazoles; Middle Aged; Neoplasm Metastasis; Pyrimidines; Retrospective Studies; Salvage Therapy; Sarcoma; Sulfonamides; Survival Analysis; Uterine Neoplasms | 2018 |
Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Progression-Free Survival; Prospective Studies; Pyrimidines; Retrospective Studies; Sulfonamides; Treatment Outcome | 2018 |
Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting.
Topics: Aged; Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Nephrectomy; Nivolumab; Probability; Prognosis; Proportional Hazards Models; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Sex Factors; Sulfonamides; Sunitinib; Survival Rate; Thrombocytosis | 2018 |
Reintroducing Pazopanib Reverses the Primary Resistance of Nivolumab in a Patient With Metastatic Clear-cell Renal Cell Carcinoma.
Topics: Aged; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Drug Synergism; Humans; Indazoles; Kidney Neoplasms; Neoplasm Metastasis; Nivolumab; Pyrimidines; Sulfonamides; Treatment Outcome | 2018 |
A Case Report of Metastatic Primary Thyroid Leiomyosarcoma Treated with Pazopanib.
Topics: Aged; Antineoplastic Agents; Female; Humans; Indazoles; Leiomyosarcoma; Neoplasm Metastasis; Pyrimidines; Sulfonamides; Thyroid Neoplasms | 2018 |
Combination therapy with local radiofrequency ablation and YC-1 inhibits the proliferation and metastasis of hepatocellular carcinoma through activating β-catenin signaling.
Topics: Animals; Apoptosis; beta Catenin; Catheter Ablation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Combined Modality Therapy; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Indazoles; Liver Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation | 2016 |
Pazopanib-related tumor lysis syndrome in metastatic clear cell renal cell carcinoma: a case report.
Topics: Carcinoma, Renal Cell; Fatal Outcome; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Patient Admission; Pyrimidines; Sulfonamides; Tumor Lysis Syndrome | 2018 |
Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: a case report.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cell Line, Tumor; Combined Modality Therapy; Hemangiosarcoma; Humans; Immunohistochemistry; Immunotherapy, Adoptive; Indazoles; Liver Neoplasms; Magnetic Resonance Imaging; Male; Neoplasm Metastasis; Neoplasm Staging; Programmed Cell Death 1 Receptor; Pyrimidines; Sulfonamides; Treatment Outcome | 2018 |
Clinical Benefit from Tyrosine Kinase Inhibitors in Metastatic Merkel Cell Carcinoma: A Case Series of 5 Patients.
Topics: Aged; Angiogenesis Inhibitors; Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Merkel Cell; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Skin Neoplasms; Sulfonamides | 2018 |
Middle East observational study in metastatic soft tissue sarcoma: an epidemiological study on the treatment patterns (MOON).
Topics: Adult; Africa, Northern; Aged; Aged, 80 and over; Drug Therapy; Female; Humans; Indazoles; Male; Middle Aged; Middle East; Neoplasm Metastasis; Pyrimidines; Radiotherapy; Retrospective Studies; Sarcoma; Sulfonamides; Surgical Procedures, Operative | 2018 |
Aortic Dissection and Cardiac Dysfunction Emerged Coincidentally During the Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal Cell Carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Aortic Dissection; Axitinib; Carcinoma, Renal Cell; Heart Diseases; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Vascular Endothelial Growth Factor A | 2018 |
OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers.
Topics: Breast Neoplasms; Drug Resistance, Neoplasm; Female; Hep G2 Cells; Humans; Indazoles; Liver Neoplasms; Male; MCF-7 Cells; MicroRNAs; Neoplasm Metastasis; Phenylurea Compounds; RNA, Neoplasm | 2018 |
Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Autophagy; Autophagy-Related Proteins; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indazoles; Kidney Neoplasms; Liquid Biopsy; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Polymorphism, Genetic; Prognosis; Pyrimidines; Retrospective Studies; Sulfonamides; Survival Rate | 2018 |
β-hCG promotes epithelial ovarian cancer metastasis through ERK/MMP2 signaling pathway.
Topics: Animals; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chorionic Gonadotropin, beta Subunit, Human; Female; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Indazoles; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Piperazines; Receptors, LH | 2019 |
Assessing Outcomes and Prognostic Factors for First-Line Therapy in Elderly Patients With Metastatic Renal Cell Carcinoma: Real-Life Data From a Single United Kingdom Institution.
Topics: Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Multivariate Analysis; Neoplasm Metastasis; Outcome Assessment, Health Care; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; United Kingdom | 2019 |
Folic Acid Reduces Mucositis in Metastatic Renal Cell Carcinoma Patients: A Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Everolimus; Female; Folic Acid; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Mucositis; Neoplasm Metastasis; Pyrimidines; Retrospective Studies; Sirolimus; Sulfonamides; Sunitinib; Treatment Outcome | 2019 |
Inhibition of ERK1/2 in cancer-associated pancreatic stellate cells suppresses cancer-stromal interaction and metastasis.
Topics: Animals; Autophagy; Carcinoma, Pancreatic Ductal; Cell Communication; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chloroquine; Drug Synergism; Epithelial-Mesenchymal Transition; Humans; Indazoles; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Metastasis; Pancreatic Neoplasms; Pancreatic Stellate Cells; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Stromal Cells; Xenograft Model Antitumor Assays | 2019 |
Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Patient Safety; Prognosis; Prospective Studies; Pyrimidines; Risk Factors; Sulfonamides; Survival Rate; Young Adult | 2019 |
Real-World Evidence Data on Metastatic Renal-Cell Carcinoma Treatment in Austria: The RELACS Study.
Topics: Aged; Antineoplastic Agents; Austria; Carcinoma, Renal Cell; Clinical Decision-Making; Electronic Health Records; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Retrospective Studies; Sex Characteristics; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome | 2019 |
[18F]-FLT positron emission tomography can be used to image the response of sensitive tumors to PI3-kinase inhibition with the novel agent GDC-0941.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dideoxynucleosides; Disease Models, Animal; Female; HCT116 Cells; Humans; Indazoles; Mice; Neoplasm Metastasis; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Positron-Emission Tomography; Signal Transduction; Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma.
Topics: Animals; Caspase 3; Cell Line, Tumor; Chemoradiotherapy; Enzyme Inhibitors; Female; Histones; Humans; Indazoles; Mice; Neoplasm Metastasis; Neuroblastoma; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Radiation-Sensitizing Agents | 2013 |
Inhibiting the phosphatidylinositide 3-kinase pathway blocks radiation-induced metastasis associated with Rho-GTPase and Hypoxia-inducible factor-1 activity.
Topics: Animals; Cell Line, Tumor; Cell Movement; Female; Humans; Hypoxia-Inducible Factor 1; Indazoles; Mice; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; rho GTP-Binding Proteins; Signal Transduction; Sulfonamides; Thyroid Neoplasms | 2013 |
Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Gene Expression; Hepatocyte Growth Factor; Humans; Indazoles; Lung Neoplasms; Mice; Neoplasm Metastasis; Niacinamide; Oncogene Proteins; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-met; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.
Topics: Administration, Metronomic; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Inhibitory Concentration 50; Irinotecan; Mice, SCID; Neoplasm Metastasis; Neoplasm Staging; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Topotecan; Treatment Outcome | 2014 |
[Metastasized renal cell carcinoma - research subjects needed!].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administration Schedule; Humans; Indazoles; Kidney Neoplasms; Multicenter Studies as Topic; Neoplasm Metastasis; Niacinamide; Patient Selection; Phenylurea Compounds; Pyrimidines; Randomized Controlled Trials as Topic; Sorafenib; Sulfonamides | 2014 |
Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma.
Topics: Aged; Carcinoma, Renal Cell; Cone-Beam Computed Tomography; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Positron-Emission Tomography; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome | 2014 |
Hypoxia promotes HO-8910PM ovarian cancer cell invasion via Snail-mediated MT1-MMP upregulation.
Topics: Animals; Cell Culture Techniques; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Chorioallantoic Membrane; Collagen Type I; Extracellular Matrix; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Indazoles; Matrix Metalloproteinase 14; Neoplasm Invasiveness; Neoplasm Metastasis; Ovarian Neoplasms; RNA, Small Interfering; Snail Family Transcription Factors; Transcription Factors; Up-Regulation | 2015 |
Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib.
Topics: Administration, Metronomic; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Synergism; Humans; Indazoles; Kidney Neoplasms; Maximum Tolerated Dose; Neoplasm Metastasis; Pyrimidines; Sulfonamides; Survival Analysis; Topotecan; Xenograft Model Antitumor Assays | 2015 |
Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series.
Topics: Adult; Aged; Disease-Free Survival; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sarcoma; Sulfonamides | 2015 |
Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Everolimus; Female; Humans; Immunotherapy; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Cells; Neoplasm Metastasis; Programmed Cell Death 1 Receptor; Pyrimidines; Pyrroles; Sirolimus; Sulfonamides; Sunitinib; T-Lymphocytes; Treatment Outcome | 2015 |
Sequential molecularly targeted drug therapy including axitinib for a patient with end-stage renal failure and metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Axitinib; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Renal Dialysis; Renal Insufficiency, Chronic | 2016 |
Next-Generation Sequencing and In Silico Analysis Facilitate Prolonged Response to Pazopanib in a Patient With Metastatic Urothelial Carcinoma of the Renal Pelvis.
Topics: Carcinoma, Transitional Cell; Computer Simulation; Female; High-Throughput Nucleotide Sequencing; Humans; Indazoles; Kidney Pelvis; Middle Aged; Models, Molecular; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, ErbB-2; Receptor, Platelet-Derived Growth Factor beta; Sulfonamides; Urothelium | 2015 |
Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Crizotinib; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Hyaluronan Receptors; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mice, Nude; Mice, Transgenic; Mutation; Neoplasm Metastasis; Pancreatic Neoplasms; Peptides; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Rats; RNA, Messenger; Signal Transduction; Sulfonamides; Time Factors; Transfection; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2016 |
Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
Topics: Adult; Aged; Biomarkers, Tumor; Cohort Studies; Exome; Female; Genome, Human; High-Throughput Nucleotide Sequencing; Humans; Indazoles; Intestinal Neoplasms; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins B-raf; Pyrimidines; Stomach Neoplasms; Sulfonamides | 2016 |
Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Time Factors; Withholding Treatment | 2016 |
Fuhrman Grade and Neutrophil-To-Lymphocyte Ratio Influence on Survival in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Leukocyte Count; Lymphocyte Count; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Prescribing Preferences in the First-Line Treatment for Patients With Metastatic Renal Cell Carcinoma in the United States.
Topics: Aged; Carcinoma, Renal Cell; Drug Prescriptions; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Practice Guidelines as Topic; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; United States | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Remission Induction; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Tumor Burden | 2016 |
Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome; Young Adult | 2016 |
Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Logistic Models; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib; Time Factors | 2016 |
Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in Japan.
Topics: Adult; Aged; Aged, 80 and over; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Japan; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quality of Life; Retrospective Studies; Survival Analysis; Treatment Outcome | 2017 |
A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome | 2016 |
Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chondrosarcoma; Disease Progression; Drug Administration Schedule; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Retrospective Studies; Sarcoma; Sirolimus; Sulfonamides; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Changes in metabolic profile, iron and ferritin levels during the treatment of metastatic renal cancer - A new potential biomarker?
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cholesterol; Ferritins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Hypothyroidism; Indazoles; Indoles; Iron; Kidney Neoplasms; Lipids; Metabolome; Models, Theoretical; Neoplasm Metastasis; Prognosis; Pyrimidines; Pyrroles; Sirolimus; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Triglycerides | 2016 |
Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Retrospective Studies; Sulfonamides; Survival Analysis; Treatment Outcome; Young Adult | 2017 |
Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Tumor Burden | 2017 |
[Relationship between treatment-related hypertension and therapeutic efficacy of vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell carcinoma].
Topics: Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypertension; Indazoles; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Nephrectomy; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors.
Topics: Aged; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Survival Rate | 2017 |
An impressive response to pazopanib in a patient with metastatic endometrial carcinoma.
Topics: Abdominal Wall; Angiogenesis Inhibitors; Carcinoma, Endometrioid; Chemoradiotherapy, Adjuvant; Endometrial Neoplasms; Female; Humans; Hysterectomy; Indazoles; Intestinal Fistula; Middle Aged; Neoplasm Metastasis; Ovariectomy; Pyrimidines; Remission Induction; Salpingectomy; Soft Tissue Neoplasms; Sulfonamides | 2016 |
Tumour response in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors - assessment of intra-tumour heterogeneity.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Genetic Heterogeneity; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pharmacogenomic Testing; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Response Evaluation Criteria in Solid Tumors; Sulfonamides; Sunitinib | 2016 |
Role of Molecular Profiling in Diagnosis of Papillary Renal-cell Cancer Presenting as Cancer of Unknown Primary Site.
Topics: Adult; Aged; Carcinoma, Renal Cell; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Neoplasms, Unknown Primary; Pyrimidines; Sensitivity and Specificity; Sulfonamides; Treatment Outcome | 2017 |
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chi-Square Distribution; DNA Primers; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease | 2008 |
Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma.
Topics: Aged; Base Sequence; Biomarkers; Carcinoma, Merkel Cell; DNA Mutational Analysis; Fatal Outcome; Female; Humans; Indazoles; Keratins; Mutation; Neoplasm Metastasis; Phosphopyruvate Hydratase; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Scalp; Skin Neoplasms; Sulfonamides | 2009 |
Rapamycin sensitizes Akt inhibition in malignant human breast epithelial cells.
Topics: Breast Neoplasms; Cell Cycle; Cell Division; Cell Line, Tumor; Enzyme Activation; Epithelial Cells; Female; Fibrocystic Breast Disease; Flow Cytometry; Humans; Immunoblotting; Indazoles; Indoles; Neoplasm Metastasis; Proto-Oncogene Proteins c-akt; Sirolimus; Survivors | 2010 |
Monoamine carboxylate transporters are involved in BI-1-associated cancer metastasis in HT1080 colon fibrosarcoma cells.
Topics: Apoptosis Regulatory Proteins; Cell Death; Cell Line, Tumor; Colonic Neoplasms; Extracellular Space; Fibrosarcoma; Gene Expression; Homeostasis; Humans; Hydrogen-Ion Concentration; Indazoles; Membrane Proteins; Neoplasm Metastasis; Sodium-Hydrogen Exchangers; Vesicular Monoamine Transport Proteins | 2011 |
Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Fatigue; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Thrombocytopenia; Treatment Outcome; Young Adult | 2012 |
Second-line treatment for renal cell cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Prognosis; Pyrimidines; Pyrroles; Retreatment; Sulfonamides; Sunitinib | 2012 |
Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CCL2; Female; Humans; Indazoles; Macrophages; Male; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Neoplasm Transplantation; NF-kappa B; Propionates; Prostatic Neoplasms; Signal Transduction | 2012 |
YC-1 exerts inhibitory effects on MDA-MB-468 breast cancer cells by targeting EGFR in vitro and in vivo under normoxic condition.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; G1 Phase; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Oxygen; RNA, Messenger; STAT3 Transcription Factor; Tumor Burden | 2012 |
Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyroid Diseases; Thyroid Gland; Thyrotoxicosis | 2012 |
Reversible posterior leukoencephalopathy syndrome induced by pazopanib.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Neoplasm Metastasis; Posterior Leukoencephalopathy Syndrome; Pyrimidines; Sulfonamides | 2012 |
Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Cohort Studies; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; United States | 2013 |
Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Aurora Kinases; Cell Cycle; Cell Line, Tumor; Cell Separation; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Indazoles; Mice; Mice, Nude; Mitosis; Neoplasm Metastasis; Neoplasm Transplantation; Paclitaxel; Protein Serine-Threonine Kinases; Pyrimidines; RNA, Small Interfering; Sulfonamides; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Tubulin Modulators | 2013 |
Ultralow doses of various drugs in chemotherapy of experimental tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Indazoles; Leukemia P388; Lung Neoplasms; Melanoma; Mice; Mitomycin; Neoplasm Metastasis; Neoplasms, Experimental; Triazoles; Xenograft Model Antitumor Assays | 2003 |
Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Collagen; Drug Combinations; Drug Screening Assays, Antitumor; Green Fluorescent Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Laminin; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Proteoglycans | 2007 |
Anticancer mechanisms of YC-1 in human lung cancer cell line, NCI-H226.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dose-Response Relationship, Drug; G1 Phase; Humans; Indazoles; Lung Neoplasms; Mitogen-Activated Protein Kinases; Neoplasm Metastasis | 2008 |
A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Humans; Indazoles; Magnetic Resonance Spectroscopy; Menopause; Middle Aged; Neoplasm Metastasis; Receptors, Estrogen | 1991 |
Phase II study of lonidamine in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Humans; Indazoles; Middle Aged; Neoplasm Metastasis; Pyrazoles | 1989 |
Metastatic Leydig cell tumor of the testis. Report of three cases and review of the literature.
Topics: Adult; Aged; Humans; Indazoles; Leydig Cell Tumor; Male; Middle Aged; Neoplasm Metastasis; Testicular Neoplasms | 1986 |
Phase II study of lonidamine in patients with metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group Study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Canada; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Indazoles; Middle Aged; Neoplasm Metastasis; Pyrazoles; Receptors, Estrogen | 1986 |